Table 1.
Characteristics of matched cases and controls
| Characteristic | Cases | Controls |
|---|---|---|
| Number of individuals | 4836 | 18,356 |
| Female sex, no. (%) | 1876 (38.8) | 7164 (39.0) |
| Age (years), mean ± SD | 61.6 (15.5) | 61.3 (15.3) |
| Years of follow-up, mean ± SD | 5.0 (3.7) | 5.0 (3.7) |
| Body mass index, mean ± SD | 28.1 (5.9) | 27.7 (5.7) |
| Charlson co-morbidity index, mean ± SD | 1.32 (1.61) | 1.27 (1.64) |
| Hypothyroidism, no. (%) | 365 (7.6) | 1296 (7.1) |
| Hyperparathyroidism, no. (%) | 17 (0.3) | 61 (0.3) |
| Current smokers, no. (%) | 765 (16.1) | 3371 (18.8) |
| Oral corticosteroid therapy,a no. (%) | 522 (10.8) | 911 (5.0) |
| Injectable corticosteroid therapy,a no. (%) | 43 (0.9) | 32 (0.2) |
| Statin therapy,a no. (%) | 326 (20.7) | 1240 (20.6) |
| Current fluoroquinolone exposure, no. (%) | 111 (2.3) | 236 (1.3) |
| Current co-amoxiclav exposure, no. (%) | 98 (2.0) | 314 (1.7) |
| Prior history of tendon rupture, no. (%) | 133 (2.8) | 114 (0.6) |
aAt least one prescription within 90 days of the index date. Current fluoroquinolone exposure = prescription within 30 days of the index date